Does Highmark cover Zepbound, Wegovy, Saxenda and Foundayo?
The short answer
Highmark covers Zepbound only on commercial and Healthcare Reform plans that include the anti-obesity benefit, where pharmacy policy J-1388 (Enhanced) makes it the plan-preferred GLP-1 with prior authorization. Adults need a baseline BMI of 40 or more plus specified obesity-related conditions, and 6 months of diet and activity changes. Wegovy, Saxenda and Foundayo also require a documented intolerance or contraindication to Zepbound.
Key takeaways
- Ask Highmark first whether your plan includes the anti-obesity benefit and whether Enhanced policy J-1388 applies.
- Under that policy, adults need a baseline BMI of 40 or more plus a listed condition. The BMI alone isn't enough.
- You also need at least 6 months of healthy dietary changes and increased physical activity before starting.
- Wegovy, Saxenda and Foundayo need a documented intolerance or contraindication to plan-preferred Zepbound.
- The policy's criteria require no type 2 diabetes diagnosis and no use with another GLP-1.
What the published policies say
Highmark: Foundayo commercial non preferred
For Highmark commercial and Healthcare Reform plans that include the anti-obesity benefit under the Enhanced policy, Foundayo needs prior authorization and is not the preferred drug. Adults must meet the strict BMI and condition criteria and must also have a documented intolerance or contraindication to Zepbound.
- Plan must include the anti-obesity benefit
- Age 18 or older, using the drug for chronic weight management
- Baseline BMI of 40 or more, plus specified obesity-related conditions
- Healthy dietary changes and increased physical activity for at least 6 months before starting
- Documented intolerance or contraindication to plan-preferred Zepbound
When a benefit, initiation of Saxenda (liraglutide), Foundayo, Wegovy, or Zepbound may be approved when all of the following criteria are met (1. through 8.): ... contraindication (specifically, documented allergic reaction, hypersensitivity) to plan-preferred Zepbound.
Highmark: Saxenda commercial non preferred
For Highmark commercial and Healthcare Reform plans that include the anti-obesity benefit under the Enhanced policy, Saxenda needs prior authorization and is not the preferred drug. Adults must meet the strict BMI and condition criteria, have a documented intolerance or contraindication to Zepbound, and for brand Saxenda must also have failed or not tolerated generic liraglutide.
- Plan must include the anti-obesity benefit
- Adults: baseline BMI of 40 or more, plus specified obesity-related conditions
- Healthy dietary changes and increased physical activity for at least 6 months before starting
- Documented intolerance or contraindication to plan-preferred Zepbound
- Brand Saxenda: therapeutic failure or intolerance to plan-preferred generic liraglutide
When a benefit, initiation of Saxenda (liraglutide), Foundayo, Wegovy, or Zepbound may be approved when all of the following criteria are met (1. through 8.): ... contraindication (specifically, documented allergic reaction, hypersensitivity) to plan-preferred Zepbound. ... intolerance to plan-preferred generic liraglutide.
Highmark: Wegovy commercial non preferred
For Highmark commercial and Healthcare Reform plans that include the anti-obesity benefit under the Enhanced policy, Wegovy needs prior authorization and is not the preferred drug. Adults must meet the same strict criteria as for Zepbound (baseline BMI of 40 or more plus specified conditions) and must also have a documented intolerance or contraindication to Zepbound.
- Plan must include the anti-obesity benefit
- Age 18 or older, using the drug for chronic weight management
- Baseline BMI of 40 or more, plus prediabetes with high triglycerides and low HDL, or specified obesity-related organ conditions
- Healthy dietary changes and increased physical activity for at least 6 months before starting
- Documented intolerance or contraindication to plan-preferred Zepbound
When a benefit, initiation of Saxenda (liraglutide), Foundayo, Wegovy, or Zepbound may be approved when all of the following criteria are met (1. through 8.): ... contraindication (specifically, documented allergic reaction, hypersensitivity) to plan-preferred Zepbound.
Highmark: Zepbound commercial preferred
For Highmark commercial and Healthcare Reform plans that include the anti-obesity benefit under the Enhanced policy, Zepbound is the plan-preferred GLP-1 for weight loss and needs prior authorization. The bar is high: adults need a baseline BMI of 40 or more plus specified obesity-related conditions, and six months of documented diet and activity changes.
- Plan must include the anti-obesity benefit
- Age 18 or older, using the drug for chronic weight management
- Baseline BMI of 40 or more, plus prediabetes with high triglycerides and low HDL, or specified obesity-related organ conditions
- Healthy dietary changes and increased physical activity for at least 6 months before starting
- No type 2 diabetes diagnosis and no use with another GLP-1 drug
When a benefit, initiation of Saxenda (liraglutide), Foundayo, Wegovy, or Zepbound may be approved when all of the following criteria are met (1. through 8.): ... contraindication (specifically, documented allergic reaction, hypersensitivity) to plan-preferred Zepbound.
Policies differ between plans from the same insurer and change during the year. Your own plan documents decide.
Highmark’s rules for weight-loss GLP-1s sit in a pharmacy policy bulletin numbered J-1388, the “Anti-Obesity (Enhanced)” policy for Commercial and Healthcare Reform plans. The version in our records is J-1388-028. Two words in that title set the scope. “Enhanced” tells you this is one variant of Highmark’s anti-obesity policy, and it’s the only one we hold. “Commercial and Healthcare Reform” tells you which plans it’s written for.
It starts with “when a benefit”
The criteria open with the words “When a benefit.” The policy applies only to plans that include the anti-obesity benefit. If your Highmark plan doesn’t include it, these medicines aren’t covered for weight loss and the criteria never come up.
The criteria for adults
For plans with the benefit, the policy says a medicine “may be approved when all of the following criteria are met (1. through 8.).” These are the points in our record:
- Age 18 or older, using the drug for chronic weight management.
- A baseline BMI (your body mass index before treatment) of 40 or more.
- In addition to that BMI: prediabetes with high triglycerides and low HDL, or specified obesity-related organ conditions.
- Healthy dietary changes and increased physical activity for at least 6 months before starting.
- No type 2 diabetes diagnosis.
- No use with another GLP-1 drug.
This is a narrow gate. Several insurers we track start at a BMI of 30, or 27 with a weight-related condition. Here, a BMI of 40 is required and isn’t enough alone. One of the listed conditions must be documented as well. If you’re close to these thresholds, ask your prescriber’s office to check exactly which conditions the bulletin lists before they submit.
Zepbound is preferred, and everything else goes through it
Zepbound is the plan-preferred GLP-1 under this policy. Wegovy, Saxenda and Foundayo are non-preferred. To get one of them, you must meet every criterion above and also have a documented intolerance or contraindication to Zepbound. A contraindication is a medical reason you can’t take a drug. The bulletin’s wording for it is specific: “documented allergic reaction, hypersensitivity.”
Brand Saxenda has a further step. The request must also show therapeutic failure or intolerance to the plan-preferred generic liraglutide.
So the order on this policy is Zepbound first. A request for Wegovy, Saxenda or Foundayo should say what happened with Zepbound, because the criteria ask for it.
What to do next
- Confirm the benefit and the policy. Ask Highmark whether your plan includes the anti-obesity benefit and whether the Enhanced policy J-1388 is the one that applies. Plans within Highmark differ.
- Build the file. You’ll need your baseline BMI with the date it was measured, lab results or diagnoses supporting the required condition, and notes showing 6 months of dietary change and activity. The prior authorization checklist shows how to organize it.
- For a non-preferred drug, include the documentation of what happened on Zepbound.
- If you’re denied, ask which numbered criterion wasn’t met. Our guide to appealing explains the next steps, and the appeal letter generator drafts a letter that asks the plan for its criteria in writing.
If you’re approved, the Lilly savings card can reduce a covered Zepbound pen fill to as little as $25, subject to its caps. If your plan lacks the benefit or you don’t meet the criteria, the Zepbound and Wegovy guides list the self-pay prices, starting at $299 and $149 a month. See the insurance guide for the wider picture.
Frequently asked questions
Does Highmark cover Zepbound for weight loss?
Only on plans that include the anti-obesity benefit, and with prior authorization. Under the Enhanced policy J-1388, Zepbound is the plan-preferred GLP-1. Adults need a baseline BMI of 40 or more plus prediabetes with high triglycerides and low HDL, or specified obesity-related organ conditions. They also need at least 6 months of healthy dietary changes and increased physical activity.
Does Highmark cover Wegovy?
Under policy J-1388, Wegovy isn't the preferred drug. On plans with the anti-obesity benefit, adults must meet the same criteria as for Zepbound, including a baseline BMI of 40 or more plus specified conditions. They must also have a documented intolerance or contraindication to plan-preferred Zepbound.
What BMI does Highmark require for weight loss medication?
The Enhanced anti-obesity policy in our records asks adults for a baseline BMI of 40 or more, together with prediabetes with high triglycerides and low HDL, or specified obesity-related organ conditions. That's higher than the BMI of 30 used by several other insurers we track. A different Highmark policy may apply to your plan.
Can I get Zepbound from Highmark if I have type 2 diabetes?
Not under this policy. The Enhanced anti-obesity criteria require no type 2 diabetes diagnosis and no use with another GLP-1 drug. The policy we hold covers the anti-obesity medicines only, so ask Highmark which policy applies to GLP-1 medicines prescribed for type 2 diabetes.
Sources (5)
- 1.Highmark: Pharmacy Policy Bulletin: J-1388 Anti-Obesity (Enhanced) – Commercial and Healthcare Reform (Version J-1388-028)
“When a benefit, initiation of Saxenda (liraglutide), Foundayo, Wegovy, or Zepbound may be approved when all of the following criteria are met (1. through 8.): ... contraindication (specifically, documented allergic reaction, hypersensitivity) to plan-preferred Zepbound.”
- 2.Highmark: Pharmacy Policy Bulletin: J-1388 Anti-Obesity (Enhanced) – Commercial and Healthcare Reform (Version J-1388-028)
“When a benefit, initiation of Saxenda (liraglutide), Foundayo, Wegovy, or Zepbound may be approved when all of the following criteria are met (1. through 8.): ... contraindication (specifically, documented allergic reaction, hypersensitivity) to plan-preferred Zepbound. ... intolerance to plan-preferred generic liraglutide.”
- 3.
- 4.
- 5.
Related pages
- What insurance covers Wegovy, Zepbound and other GLP-1 medicines?
- Wegovy and Zepbound prior authorization: a criteria checklist
- How to appeal a Wegovy or Zepbound insurance denial
- What is Zepbound? Uses, cost, doses and side effects
- What is Wegovy? Uses, doses, pill and pen, and cost
- Appeal letter generator
